 Up-regulated ling cancer 10 URLC10, TTK protein kinase TTK and K homology domain containing protein over expressed in cancer KOC1 were identified as new targets of tumor associated antigens using cDNA microarray technologies combined with the expression profiles of normal and cancer tissues. Furthermore, anti-angiogenic therapy is now considered to be one of promising approaches for treating cancer. Vascular endothelial growth factor receptor 1 VEGFR1 and vascular endothelial growth factor receptor 2 VEGFR2 are essential targets for tumor angiogenesis. Epitope peptides for these targets are able to induce cytotoxic T lymphocytes CTL restricted to HLA-A 2402 in vivo. On the other hand, chemotherapy CDDP, 5-FU plus radiation therapy has been to be a standard treatment for unresectable advanced esophageal cancer. In this clinical trial, we evaluate the safety and immune responses of different doses of multiple peptides URLC10, TTK, KOC1, VEGFR1, and VEGFR 2 emulsified with Montanide ISA 51 in combination with chemotherapy CDDP, 5-FU plus radiation therapy in treating patients with unresectable, advanced or recurrent esophageal cancer. 